Ukraine Advances Access to Innovative Therapies through HTA and Managed Entry Agreements
Ukraine continues to strengthen its healthcare system through significant reforms in pricing, reimbursement, and access to innovative therapies.
Since 2021, the Government of Ukraine has adopted regulations on health technology assessment (HTA) and managed entry agreements (MEA), as well as national guidelines for HTA of medicines, gradually aligning the country’s approach with best international practices. These efforts aim to boost the pharmacoeconomics based decision-making on coverage and reimbursement, promote access to effective health technologies, and ensure greater transparency in public healthcare funding.
From 2021 on CMS Life Sciences and Healthcare team in Ukraine has been at the forefront of HTA and MEA, advising global innovative life sciences clients on market access strategies, HTA, centralised, regional, local and hospital procurement, pricing, reimbursement and MEA. CMS has also represented leading global pharmaceutical companies in dialogue with the key stakeholders concerning HTA, pricing and reimbursement.
CMS Analysis
Our lawyers have prepared a detailed overview of developments in HTA and MEA in Ukraine. The analysis includes:
- A timeline of legislative and practical milestones of HTA and MEA
- Key statistics on HTA procedures, dossier types, therapeutic areas, and signed MEAs
- Practical takeaways from implementation experience
- Insights into ongoing policy dialogue and expected further legislative and regulatory developments
